Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;110(4):1028-1033.
doi: 10.3324/haematol.2024.286658. Epub 2024 Nov 28.

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials

Enrica Antonia Martino  1 , Daniele Derudas  2 , Elena Rossi  3 , Sofia Terlizzi  4 , Giovanni Reddiconto  5 , Paola Stefanoni  6 , Jacopo Micozzi  7 , Silvia Mangiacavalli  8 , Elena Zamagni  9 , Massimo Offidani  10 , Anna Furlan  11 , Gabriele Buda  12 , Flavia Lotti  13 , Carmine Liberatore  14 , Antonio Lazzaro  15 , Roberta Della Pepa  16 , Giuseppe Bertuglia  17 , Emiliano Barbieri  18 , Concetta Conticello  19 , Claudio De Magistris  20 , Lorenzo De Paoli  21 , Velia Bongarzoni  22 , Anna Maria Cafro  23 , Anna Mele  24 , Pietro Benvenuti  25 , Claudio Cerchione  26 , Cirino Botta  27 , Elisabetta Antonioli  28 , Nicola Sgherza  29 , Sara Aquino  30 , Giuseppe Mele  31 , Gregorio Barilà  32 , Salvatore Palmieri  33 , Ombretta Annibali  34 , Rosario Bianco  35 , Massimiliano Arangio Febbo  36 , Gloria Margiotta Casaluci  37 , Angela Rago  38 , Raffaele Fontana  39 , Francesca Farina  40 , Ernesto Vigna  1 , Antonella Bruzzese  1 , Katia Mancuso  9 , Davide Nappi  25 , Sonia Morè  10 , Elena Rivolti  18 , Catello Califano  41 , Angela Amendola  42 , Daniela Roccotelli  43 , Alessandra Lombardo  44 , Annalisa Citro  45 , Giuseppina Uccello  46 , Renato Zambello  47 , Alessandro Maggi  48 , Santo Neri  49 , Michele Monachesi  13 , Alessandro Gozzetti  50 , Vittorio Montefusco  51 , Marino Brunori  52 , Emilia Cotzia  53 , Giuseppe Pietrantuono  54 , Angela Maria Quinto  55 , Valeria Amico  56 , Nicola Di Renzo  5 , Marta Coscia  24 , Monica Galli  6 , Valerio De Stefano  3 , Maria Teresa Petrucci  7 , Antonino Neri  57 , Francesco Di Raimondo  18 , Fortunato Morabito  58 , Pellegrino Musto  59 , Massimo Gentile  60
Affiliations

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials

Enrica Antonia Martino et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan Meier curves for all 270 relapsed / refractory multiple myeloma patients treated with isatuximab, pomalidomide, and dexamethasone. (A) Progression-free survival (PFS). (B) PFS according to daratumumab exposure. (C) Overall survival (OS). (D) OS according to daratumumab exposure. (E) Time-to-next treatment (TTNT). (F) PFS according to cytogenetic risk. (G) Cytogenetic risk. RRMM: relapsed/refractory multiple myeloma; IsaPd: isatuximab, pomalidomide, and dexamethasone.
See this image and copyright information in PMC

References

    1. Attal M, Richardson PG, Rajkumar SV, et al. . Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2072. - PubMed
    1. Richardson PG, Perrot A, Miguel JS, et al. . Isatuximabpomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024;109(7):2239-2249. - PMC - PubMed
    1. Dimopoulos MA, Oriol A, Nahi H, et al. . Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(4):1319-1331. - PubMed
    1. Attal M, Richardson PG, Rajkumar SV, et al. . Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107. - PubMed
    1. Moreau P, Dimopoulos MA, Mikhael J, et al. . Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. - PubMed

LinkOut - more resources